MK-2206 window of opportunity study in breast cancer

Abstract

The course of drug discovery and development is expensive, and takes 10–15 years with a high failure rate. Promising candidate drugs that pass in vitro investigations undergo in vivo testing for efficacy and safety. Novel cancer treatments are often assessed in patients who did not benefit from standard treatments. These heavily pretreated patients may have developed significant heterogeneity and multidrug resistance. They may also have a high tumor burden, which may limit activity of novel agents and stop their future development.